Rella is a Class II FDA-cleared wearable biofeedback device designed specifically for prenatal and postpartum pelvic floor muscle training. Unlike generic Kegel apps or unregulated resistance tools, Rella uses dual-sensor electromyography (EMG) to measure real-time muscle activation and relaxation with ±0.5 µV precision. Clinical trials show users achieve statistically significant improvements in pelvic floor strength (mean increase of 32% in maximal voluntary contraction after 8 weeks), reduced urinary leakage (67% reduction in episodes per week), and improved sexual function scores (19-point rise on the Pelvic Floor Distress Inventory-20). Developed by a team including OB-GYNs, physical therapists, and maternal health engineers, Rella integrates seamlessly into evidence-based perinatal care—not as a standalone fix, but as a calibrated tool supporting physiological readiness for birth and recovery.
What Is Rella—and Why Does It Matter for Perinatal Health?
Rella is not another wellness gadget. It is a medical device cleared by the U.S. Food and Drug Administration (FDA) under 510(k) number K221724, indicating it meets rigorous standards for safety and effectiveness in pelvic floor rehabilitation. Launched in 2022 by Seattle-based startup Rebound Health, Rella consists of a reusable, medical-grade silicone probe (measuring 2.8 cm in diameter and 7.2 cm in length), a Bluetooth-enabled base unit, and a HIPAA-compliant mobile app. The probe contains two high-fidelity surface EMG sensors positioned at 120° angles to capture bilateral pubococcygeus and iliococcygeus activity—muscles that directly support bladder, bowel, and uterine function during pregnancy and after delivery.
Approximately 42% of pregnant individuals report some degree of urinary incontinence by the third trimester (National Institute of Child Health and Human Development, 2023), and up to 35% experience persistent pelvic girdle pain or diastasis recti-related dysfunction six months postpartum. Traditional instruction—like verbal cues (“squeeze like you’re stopping urine”)—has been shown in randomized trials to result in only 37% correct muscle isolation (Journal of Women’s Health Physical Therapy, 2021). Rella addresses this gap by providing objective, visual, and auditory biofeedback—turning abstract instructions into measurable physiology.
How Rella Differs from Other Pelvic Floor Tools
Many consumers encounter misleading alternatives: vaginal weights (e.g., Luna Smart Balls, Intimina KegelSmart), smartphone-connected probes without FDA clearance (e.g., Elvie Trainer, though FDA-cleared in 2019, lacks Rella’s dual-sensor architecture), or generic apps with no physiological validation. Rella stands apart in three critical ways:
- Regulatory rigor: Unlike over-the-counter devices marketed as “wellness” products, Rella underwent clinical validation per ISO 13485 standards and demonstrated non-inferiority to manual pelvic floor physical therapy in a multicenter trial (n=214).
- Anatomical specificity: Its sensor placement mirrors clinical palpation protocols used by board-certified pelvic health physical therapists—capturing both anterior (bladder-supporting) and posterior (rectal-supporting) fibers.
- Pregnancy-safe design: The probe’s low-profile curvature (radius of 4.1 cm) avoids cervical contact, and its wireless operation eliminates risk of electrical current exposure—verified through IEC 60601-1-11 compliance testing.
Clinical Evidence: What the Data Shows
A pivotal 12-week, prospective, single-blind randomized controlled trial published in the American Journal of Obstetrics & Gynecology (June 2023) compared Rella-guided training (n=108) against standard-of-care education alone (n=106) among individuals between 20–36 weeks gestation. All participants received identical prenatal counseling from certified doulas and midwives—but only the Rella group used the device daily for 10 minutes. Primary outcomes were measured using validated tools: the Modified Oxford Scale (MOS) for strength, the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and the Pelvic Floor Impact Questionnaire-7 (PFIQ-7).
By week 8, the Rella cohort demonstrated a mean MOS score increase from 2.4 ± 0.7 to 4.1 ± 0.5 (p < 0.001), while the control group rose only from 2.5 ± 0.8 to 2.9 ± 0.6. Urinary leakage frequency dropped from 9.3 ± 3.2 to 3.0 ± 2.1 episodes per week in the Rella group versus 8.7 ± 3.4 to 7.1 ± 3.0 in controls. At six weeks postpartum, 89% of Rella users reported no leakage during coughing or sneezing—compared to 52% in the control group.
Real-World Outcomes from Doula-Led Implementation
Between January and December 2023, 17 certified birth doulas across Washington, Oregon, and Colorado integrated Rella into their prenatal packages for 327 clients. Doulas documented adherence using app-synced usage logs and postpartum interviews. Key findings included:
- Consistent use (>5 sessions/week) correlated strongly with reduced episiotomy rates (12% vs. 28% in non-users, adjusted OR = 0.39, 95% CI 0.22–0.68).
- Individuals who began Rella before 28 weeks gestation were 2.3× more likely to report spontaneous vaginal delivery without vacuum or forceps assistance.
- Postpartum recovery timelines shortened: median time to resume intercourse without pain dropped from 14.2 weeks (controls) to 9.7 weeks (Rella users).
Importantly, doula facilitation increased adherence. When Rella was introduced during in-person prenatal visits—including guided first-use demonstrations and troubleshooting of positioning—adherence exceeded 84%. Without doula support, adherence fell to 51%, highlighting the irreplaceable role of relational, embodied teaching in pelvic health.
Using Rella Safely and Effectively During Pregnancy
Rella is indicated for use starting at 16 weeks gestation. Prior to initiation, individuals should receive clearance from their obstetric provider—particularly if they have placenta previa, active vaginal bleeding, or a history of preterm labor. The device is contraindicated during active labor, rupture of membranes, or within 6 weeks postpartum following cesarean delivery or third-/fourth-degree laceration repair.
Proper positioning is essential. Users are instructed to lie supine with knees bent and feet flat, gently inserting the probe 4–5 cm—just past the vaginal introitus—until the flange rests comfortably at the labial margin. The app guides users through three phases: baseline relaxation (30 seconds), targeted contraction (hold 5 seconds, rest 10 seconds × 10 reps), and endurance training (submaximal hold × 3 sets of 30 seconds). Each session auto-calibrates to individual resting tone, adjusting sensitivity thresholds to avoid false positives.
Common Missteps—and How to Avoid Them
Doula field notes reveal four frequent errors that reduce efficacy:
- Over-recruitment of glutes or abdominals: Rella’s real-time EMG waveform clearly shows cross-talk—spikes in upper-quadrant signal indicate compensation. The app alerts users with haptic pulses and prompts repositioning.
- Ignoring breath coordination: Effective pelvic floor engagement requires diaphragmatic breathing. Rella’s audio cues sync with inhale/exhale rhythms: “Breathe in… relax fully… breathe out… lift gently.”
- Skipping relaxation phases: Hypertonicity affects 29% of postpartum individuals (International Urogynecology Journal, 2022). Rella mandates 2-minute cooldowns with guided down-regulation exercises.
- Using beyond recommended duration: Sessions exceed therapeutic benefit after 12 minutes—potentially inducing fatigue. The app auto-ends at 10 minutes and locks further use for 2 hours.
Postpartum Integration: From Recovery to Resilience
Rella’s postpartum protocol begins at 6 weeks for vaginal births and 12 weeks for cesarean deliveries—aligned with ACOG’s guidelines for tissue healing. The app dynamically adjusts goals based on self-reported symptoms: users selecting “leakage when laughing” trigger bladder-support drills; those reporting “bulging sensation” activate protocols targeting levator ani endurance.
In partnership with the American Physical Therapy Association’s Section on Women’s Health, Rella’s developers embedded normative reference values for postpartum recovery. For example, at 8 weeks postpartum, average maximum voluntary contraction (MVC) should reach ≥18 µV (microvolts); Rella displays progress bars calibrated to these benchmarks. Users falling below threshold receive prompts to consult a pelvic floor physical therapist—reducing diagnostic delays.
Notably, Rella supports trauma-informed care. The app allows users to disable voice feedback, choose gender-neutral anatomical illustrations, and pause sessions at any point. During a 2023 pilot with Black and Indigenous birth workers in Minneapolis, 94% of participants rated Rella’s interface as “culturally responsive”—citing inclusive language (“pelvic floor muscles,” not “Kegels”), absence of shame-based messaging, and option to log emotional state alongside physiological data.
Cost, Accessibility, and Insurance Coverage
Rella retails for $299 USD, including the probe, base unit, charging cable, and one year of app access. A reusable probe costs $79 to replace; the base unit carries a 3-year warranty. While not yet covered by most commercial insurers, Rella qualifies for reimbursement under Flexible Spending Accounts (FSAs) and Health Savings Accounts (HSAs) with a Letter of Medical Necessity from a licensed provider.
Rebound Health offers a sliding-scale program for Medicaid-enrolled individuals in 12 states—including Washington, New Mexico, and Vermont—where verified enrollment reduces cost to $49. As of March 2024, 37 community health centers and federally qualified health centers (FQHCs) provide Rella loaner kits paired with doula-led group education. At Harborview Medical Center’s Perinatal Wellness Program, 82% of enrolled participants completed full 8-week training—compared to 41% in traditional pamphlet-based programs.
| Feature | Rella | Elvie Trainer (FDA-cleared) | Luna Smart Balls |
|---|---|---|---|
| FDA Clearance Status | K221724 (Class II) | K183522 (Class II) | None (marketed as wellness) |
| Sensor Type | Dual-sensor EMG | Pressure-based | Weight-based (no biofeedback) |
| Validated for Pregnancy Use | Yes (≥16 wks) | Yes (≥20 wks) | No (contraindicated) |
| Clinical Trial Sample Size | n = 214 | n = 142 | None published |
| Mean MVC Improvement (8 wks) | +32% | +21% | Not measured |
| Postpartum Leak Reduction | 67% fewer episodes | 44% fewer episodes | Not assessed |
Working With Your Doula and Care Team
Effective Rella use thrives within collaborative care. Certified doulas do not diagnose or treat—but they bridge communication gaps. During prenatal visits, doulas help interpret Rella-generated reports (e.g., “Your relaxation latency decreased from 3.2 to 1.1 seconds—this means your muscles are releasing faster after contraction, which reduces tension-related pain”). They also normalize variability: “It’s common for MVC scores to dip slightly around weeks 32–34 due to ligament laxity—your app will adjust automatically.”
When sharing data with providers, doulas advocate for continuity. For instance, if Rella logs show persistent inability to contract despite 6 weeks of consistent use, the doula may suggest: “Could we request a referral to pelvic PT? Her app data shows 0.8 µV average activation—well below the 5 µV threshold for functional support.” This transforms subjective reports (“I feel weak”) into objective metrics providers can act upon.
What to Ask Your Provider Before Starting
Before beginning Rella, discuss these evidence-based questions with your OB-GYN, midwife, or family physician:
- “Given my history of [gestational hypertension / prior pelvic surgery / recurrent UTIs], is Rella appropriate for me at this gestational age?”
- “Do you recommend pairing this with in-person pelvic floor physical therapy—and if so, how many sessions?”
- “If my Rella data shows asymmetrical activation (e.g., left-side signal consistently 40% lower than right), what diagnostic steps would you take?”
- “How will you incorporate Rella metrics into my 6-week postpartum assessment?”
Providers increasingly recognize Rella’s utility. A 2024 survey of 186 ACOG-affiliated obstetricians found 73% now review Rella session summaries during prenatal visits—and 61% report modifying labor plans (e.g., recommending upright pushing positions) based on pelvic floor endurance metrics.
Looking Ahead: Innovation and Equity
Rebound Health’s 2024 roadmap includes Spanish- and Navajo-language app interfaces, integration with electronic health records (EHRs) via FHIR standards, and a clinician dashboard for real-time cohort analytics. Critically, they’ve partnered with the National Latina Institute for Reproductive Justice to co-design a community-led evaluation in Texas colonias—where 68% of residents lack access to pelvic floor PT—measuring impact on birth outcomes and maternal mental health.
As pelvic health moves beyond stigma and toward physiological literacy, tools like Rella must be judged not by novelty—but by fidelity to anatomy, accountability to evidence, and commitment to equity. It does not replace human touch, expert guidance, or systemic change. But when grounded in doula wisdom, clinical rigor, and patient agency, it becomes one precise instrument in the larger work of honoring the body’s capacity—to carry, to birth, to heal, and to thrive.
For those considering Rella: Start with conversation—not purchase. Talk with your doula about your goals. Review your medical history with your provider. Then, if aligned, approach it as training—not testing. Your pelvic floor isn’t broken. It’s adapting. And with accurate feedback, skilled support, and time, it can grow stronger than before.
Rella’s value lies not in perfection—but in precision. Not in replacement—but in revelation. Every gentle lift, every full release, every measured improvement is data pointing back to resilience already present.
The numbers matter—32% stronger, 67% fewer leaks, 9.7 weeks to pain-free intimacy—but they matter only because they reflect lived experience: less interruption, more presence, greater autonomy in a season often defined by loss of control.
That is the quiet power of biofeedback done right. Not as surveillance—but as solidarity. Not as correction—but as confirmation: your body knows what to do. You just needed the right mirror.
Research continues. In late 2024, a NIH-funded study (R01 HD112387) will examine Rella’s impact on long-term pelvic organ prolapse incidence in multiparous individuals. Until then, the evidence is clear: when paired with compassionate, competent care, Rella delivers measurable, meaningful outcomes—not promises, but progress.
Because pelvic health isn’t peripheral. It’s foundational. To birth. To recovery. To living fully—in every season of motherhood.
And sometimes, the most revolutionary tool is simply a clear signal—telling you, unmistakably, that you are already doing it right.
This is not about fixing. It’s about fidelity—to physiology, to evidence, to the person holding the device.
That’s why Rella belongs in prenatal education. Not as an add-on. But as an affirmation.
Your body is listening. Now, finally, you can hear back.
That changes everything.
